Nasdaq
$10.61▲ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $563.1MShares out 53.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.15Pre-market26.10.15 20:006-KKey event#●●●#●●●#●●●
Adlai Nortye Group Ltd.Bullish
Adlai Nortye has entered into clinical collaboration and supply agreements with Eli Lilly and Merck KGaA to evaluate the combination of its investigational drug AN4035 with cetuximab. Under these agreements, Lilly and Merck will provide cetuximab at no cost for clinical trial sites in the U.S., Australia, and China, supporting the company's ongoing global Phase I trial.…more
$10.61+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Regular26.10.01 23:044Ownership
Adlai Nortye Group Ltd.
Insider Ji Ping of Adlai Nortye Group Ltd. filed a statement regarding changes in beneficial ownership of securities as of September 29, 2026. This filing serves as an official report of the insider's equity position change to the SEC.…more
$10.61+0.09%vs prev closeView filingShare - 9.30Pre-market26.09.30 21:306-KKey event
Adlai Nortye Group Ltd.
Adlai Nortye Group Ltd. has appointed Christopher Liu, PharmD, as the new Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience in biotechnology and oncology, and he will focus on strengthening the company's engagement with the global investment community and communicating its strategic progress.…more
$10.61+0.09%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 20:00#●●●#●●●#●●●
Adlai Nortye Enters Clinical Collaboration with Lilly and Merck KGaA
Adlai Nortye has entered into clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA to evaluate its AN4035 candidate in combination with cetuximab. The collaboration supports an ongoing Phase I trial for patients with CEACAM5-enriched, RAS-addicted solid tumors.…more
$10.61+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Clinical-stage biotech company Adlai Nortye has appointed Christopher Liu as the new Head of Investor Relations and Public Relations. This move is aimed at strengthening the company's communication with the global investment community.…more
$10.61+0.09%vs prev close - 8.14Pre-market26.08.14 20:00
●●●●●●●● ●●●●● ●●●●●●
Adlai Nortye announced its first-half 2026 financial results alongside positive updates on its oncology clinical pipeline. The company is accelerating global development efforts supported by significant capital raised through recent private placements.…more
$10.61+0.09%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report